Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lynparza May Still Rival Tesaro's Niraparib In Ovarian Cancer Therapy

Executive Summary

AstraZeneca hopes "robust" data from its Phase III SOLO-2 trial will pave the way for its PARP-inhibitor Lynparza (olaparib) to be used in the US market as a maintenance therapy in BRCA-mutated second-line ovarian cancer. But some analysts think FDA may want more proof before giving the okay.

Advertisement

Related Content

AstraZeneca Mulls Broad Ovarian Cancer Maintenance Approval For Lynparza
AstraZeneca's Lynparza Looks To Hang On To Lead, With Tesaro's Niraparib On The Way
Ovarian Cancer Drugs Will Get ICER Review As Olaparib's Maintenance Indication Looms
Lynparza's Wider Prospects Boosted By Late-Stage Breast Cancer Study
Myriad's Ovarian Cancer Test Proves Its Mettle as Tesaro Companion Dx
Tesaro Takes Lead: Ovarian Cancer PhIII Pushes Niraparib Ahead Of Clovis' PARP Inhibitor
Lynparza Approval Shows Benefit/Risk Contrast In Maintenance, Relapse Settings

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097551

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel